Theralase Technologies Inc. V.TLT

Final clinical results of N-803 BCG Unresponsive NMIBC Trial

[Eoganacht]

were presented at the AUA2022 yesterday, Friday, May 13. We already knew the results - Cohort A  (83 patients with CIS) achieved - 71% CR at any time - 36% CR at 2 years.  Cohort B (77 patients with papillary disease) achieved a disease-free survival rate of 57% at 12 months and 48% at 24 months.

Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts

[Pandora]

"Dr. Chamie concluded that, among 160 patients with BCG-unresponsive NMIBC, there is a 99% bladder cancer specific overall survival at 2 years after treatment with intravesical N-803 plus BCG. In patients with CIS, a 71% CR rate was seen with 24.1 months median duration of response and 96% absence of progression to MIBC at 24 months." ?? Would anyone like to give clarification to this

[enriquesuave]

Same results as before.  Very good, but it's also a combination therapy  2 drugs will always work synergistically and give added efficacy.  TLD-1433 single agent should give us results very close to those IMO after full trial results, but we will be 1 single treatment vs 15-21 instillations.  All IMHO   

[CancerSlayer]

  If we achieve similar efficacy with only two required treatments vs 15+, that'll be a no-brainer.  Also, the BCG shortage has precluded its use in many urologic practices & a restricted supply will generally drive prices higher.   Imo, docs will continue to look for other options that are more feasible/practical for both their patients & busy practices.  If FDA

[Oilminerdeluxe]

Would not mind some action coming or way soon

[Rumpl3StiltSkin]

Because of all the reasons given, I don't think these guys are Competition to TLT. We're in pole position for treating NMIBC, I believe. And as Slayer states, TLT's 1433 should/could do much better in solid cancers, without the limitations that bladder dosimetry causes. TLT just needs that GLP work done. IMO :-)

[ScienceFirst]

Lets wait for the next 1-2 round of data in the optimized group to see where we'll land in terms of efficacy ratios at different stages (leading to 450-days).